BioPharma Dive - Latest News

Former Neumora CEO to lead Galapagos spinout

Henry Gosebruch is now chief executive of the spinout, which has roughly $2.5 billion and plans to use dealmaking to build a research pipeline targeting cancer, viruses and the immune system.

Apr 22, 2025 - 13:58
 0
Former Neumora CEO to lead Galapagos spinout

Henry Gosebruch is now chief executive of the spinout, which has roughly $2.5 billion and plans to use dealmaking to build a research pipeline targeting cancer, viruses and the immune system.

Read More

Tags:

Previous Article

Facing added pressure from Eli Lilly, Novo Nordisk submits for FDA approval of o...

Next Article

Stances on autism are reshaping the advocacy landscape

Related Posts

A new obesity biotech launches; Gilead plans to quickly advance once-yearly PrEP for HIV

A new obesity biotech launches; Gilead plans to quickly...

Mar 12, 2025  0

Tariffs raise concern among generic drugmakers, as advocacy groups seek exemptions

Tariffs raise concern among generic drugmakers, as advo...

Feb 10, 2025  0

Eli Lilly’s earnings, shares lifted by obesity drug sales

Eli Lilly’s earnings, shares lifted by obesity drug sales

Feb 9, 2025  0